ArticleFrontiers in oncology2023

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer.

Maroun Bou Zerdan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.